1993 Fiscal Year Final Research Report Summary
Effects of Doxorubicin or OK-432 on Cancer cells during liver regeneration after two-thirds hepatectomy
| Project/Area Number |
03670630
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyusyu University |
|---|
Principal Investigator |
MATSUYAMA Takashi Kyusyu Univ.Surgery II, Assistant Prof., 医学部, 講師 (00157348)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANAGA Katsuhiko Kyusyu Univ.Surgery II, Assistant Prof., 医学部, 講師 (70220176)
|
|---|
| Project Period (FY) |
1991 – 1993
|
| Keywords | liver tumor / adjuvant therapy / doxorubicin / OK-432 / liver regeneration |
|---|
| Research Abstract |
Background : Adjuvant chemotherapy may increase the salvage rate after removal of promary liver cancer, but the role of postoperative adjuvant therapy during liver regeneration remains to be clarified.
Methods : To evaluate the preventive effects of Doxorubicin or OK-432 for early hepatic recurrence, five groups of WKA rats had viable tumor cell injected directly into the portal vein after two-thirds hepatectomy. Group one was used as a control, the remaining groups had Doxorubicin injected directly into the hepatic artery : immediately, at 24 hours, 48hours, and 72 hours post-operatively. Secondly, four groups of WKA rats underwent two-thirds hepatectomy and similar injection of viable tumor cells. Group A underwent no further treatment. Group B had Doxorubicin injected 24 hours post-operatively. Group C had OK-432 administered into the subcutaneously transpositioned spleen three times prior to two-thirds hepatectomy. Group D underwent the administration of OK-432, and the Doxorubicin injection.
Results : When compared with regard to the forms of Doxorubicin administered, there was no statistical difference in survival rates between all groups. There were notable adverse side effects of persistent suppression and delay of liver cell devision after Doxorubicin administration. The mean survival period in Group A, B, C, and D was determined to be 22.6, 20.0, 38.6, and 30.9 days, respectively (p<0.01).
Conclusions : Based on the findings we believe adjuvant chemotherapy during the liver regeneration phase is not recommended. OK-432 plays an important role in the preventive effect of liver recurrence after hepatectomy.
|
